| Market Capitalization (Millions $) |
2,583 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
652 |
| Revenues (TTM) (Millions $) |
682 |
| Net Income (TTM) (Millions $) |
-19 |
| Cash Flow (TTM) (Millions $) |
121 |
| Capital Exp. (TTM) (Millions $) |
1 |
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of treatments for central nervous system (CNS) disorders. The company was founded in 2005 and is headquartered in Rockville, Maryland, USA.
Supernus has a diverse portfolio of products in various stages of development. The company's leading products include Oxtellar XR, a treatment for partial onset seizures in adults and children, and Trokendi XR, a treatment for migraines and epilepsy. Additionally, Supernus is developing other treatments for CNS disorders, including ADHD, schizophrenia, and depression.
The company's management team has extensive experience in the pharmaceutical industry and has a track record of successful drug development and commercialization. The company has a robust intellectual property portfolio, including patents for its lead products.
Supernus has a strong partnership with the FDA and has received several FDA approvals for its products. The company also focuses on the development of drugs with improved delivery methods, including sustained-release formulations and transdermal patches.
In addition to its drug development pipeline, Supernus has a strong financial position with significant cash reserves and revenue growth. The company also has partnerships with several other pharmaceutical companies to develop and commercialize their products.
Overall, Supernus Pharmaceuticals is a well-established pharmaceutical company with a strong focus on innovation and drug development for CNS disorders. The company's diverse portfolio of products, strong management team, and financial position make it a promising player in the pharmaceutical industry.
Company Address: 9715 Key West Avenue Rockville 20850 MD
Company Phone Number: 838-2500 Stock Exchange / Ticker: NASDAQ SUPN
|
0.43% 
87.74 %